Get started
NOVO NORDISK A/SNOVO NORDISK A/SNOVO NORDISK A/S

NOVO NORDISK A/S

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

NVO/N chart


Full chart

Key facts today


Novo Nordisk faces a class action lawsuit in New Jersey for allegedly misleading investors about its REDEFINE-1 trial results, causing a 17% drop in stock price.
Novo Nordisk will discontinue its Penfill and FlexPen human insulin products by late 2025, but will still provide Human Mixtard in vials and other insulins in India.
Analyze the impactAnalyze the impact

NVO/N upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.21 T‬ MXN
Dividend yield (indicated)
1.58%
Price to earnings Ratio (TTM)
21.57
Basic EPS (TTM)
69.22 MXN
Net income (FY)
‪305.35 B‬ MXN
Revenue (FY)
‪878.07 B‬ MXN
Shares float
‪3.37 B‬
Beta (1Y)
0.96

About NOVO NORDISK B A/S


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Lars Fruergaard Jørgensen
Website
novonordisk.com
Headquarters
Bagsværd
Founded
1931
FIGI
BBG007QV72Q7
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NVO/N news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NVO/N highest yielding bonds


N
XS300255582
NOVO NO.F.NL 25/37 MTN
Yield to maturity
3.60%
Maturity date
May 27, 2037
N
XS282046075
NOVO NO.F.NL 24/34 MTN
Yield to maturity
3.30%
Maturity date
May 21, 2034
N
XS300255353
NOVO NO.F.NL 25/33 MTN
Yield to maturity
3.28%
Maturity date
May 27, 2033
N
XS300255329
NOVO NO.F.NL 25/30 MTN
Yield to maturity
2.94%
Maturity date
Aug 27, 2030
N
XS282045567
NOVO NO.F.NL 24/31 MTN
Yield to maturity
2.89%
Maturity date
Jan 21, 2031
XS244124704
NOVO NO.F.NL 22/30MTN
Yield to maturity
2.84%
Maturity date
Mar 31, 2030
N
XS300255299
NOVO NO.F.NL 25/28 MTN
Yield to maturity
2.66%
Maturity date
May 27, 2028
N
XS282045460
NOVO NO.F.NL 24/29 MTN
Yield to maturity
2.59%
Maturity date
Jan 21, 2029
XS234803042
NOVO NO.F.NL 21/28
Yield to maturity
2.58%
Maturity date
Jun 4, 2028
N
XS300255213
NOVO NO.F.NL 25/27 FLRMTN
Yield to maturity
2.50%
Maturity date
May 27, 2027
XS244933017
NOVO NO.F.NL 22/27MTN
Yield to maturity
2.39%
Maturity date
Sep 30, 2027

See all NVO/N bonds 

Sparks


Curated watchlists where NVO/N is featured.

See all sparks 


Check out other big names from the same industry as NVO/N.